Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Featured News A Fresh IPO That Long-Term Investors Shouldn't IgnoreAuthored by Jordan Chussler. Article Posted: 1/14/2026. 
Key Points - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. But even conservative investors shouldn't dismiss every newly public company—some recent IPOs may justify a place in buy-and-hold portfolios. One biotechnology company in the healthcare sector that recently went public may be worth watching. Last Year's IPO Success Stories Last year provides a reminder why certain IPOs shouldn't be written off by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have profited from its nearly 359% surge within 30 days of listing, but longer-term holders are still enjoying strong returns. Other examples refute the notion that IPOs are only high-risk startups. Medical products and services provider Medline (NASDAQ: MDLN), which publicly debuted in December 2025, was founded in 1966 and already carries a market cap above $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—known for its bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it an immediate consideration for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnosis and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals pair radioactive isotopes with a targeting module that seeks specific cells (for example, cancer cells) to deliver localized doses of radiation. This approach minimizes damage to healthy tissue compared with some conventional radiation treatments. Industry consultancy Grand View Research estimates the global nuclear medicine market at nearly $18 billion in 2024, forecasting it to reach nearly $35 billion by 2030—a compound annual growth rate of about 10.16%. Grand View also notes that North America represents nearly 43% of the global market, with the United States as the dominant regional player—an important market for Boston-based Aktis Oncology. Aktis Oncology's Clinical-Stage Profile Wall Street expects biotech IPO activity to rebound in 2026 after funding cuts in 2025 slowed healthcare listings. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and generated one of the largest recent raises for a biotech. The offering brought in $318 million, and the company currently carries a market cap of about $3.34 billion. According to the company's prospectus, the executive team includes experienced drug developers and commercial leaders, with management having participated in bringing 14 currently FDA‑approved products to market. At a technical level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer drugs that uses proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not prevent it from attracting significant strategic interest. Eli Lilly (NYSE: LLY) anchored the IPO and purchased $100 million of AKTS shares, according to Reuters. The Lilly investment builds on a 2024 collaboration between the two companies to develop tumor‑targeting radiopharmaceuticals. As part of that agreement, Aktis received $60 million in cash and an equity investment from Eli Lilly, with potential milestone payments that could exceed $1 billion. The significance of Lilly's backing is notable. At about $1.01 trillion, Eli Lilly is one of the largest pharmaceutical companies by market cap; its net income rose nearly 109% year‑over‑year from 2023 to 2024. That trend may continue when Lilly reports Q4 and full‑year 2025 financials on Feb. 5. Between its equity stake and the recent $100 million share purchase, the maker of Zepbound now has a meaningful financial interest in Aktis's future success.
| 
